Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures

Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O'Brien, Ashley F. Slagle, Anna Krasnow, Matthew Reaney, Michael Baldwin, Natalia Male, Klaus B. Rohr, Jeff Swigris, Katerina Antoniou
ERJ Open Research 2022 8: 00681-2021; DOI: 10.1183/23120541.00681-2021
Marlies Wijsenbeek
1Dept of Respiratory Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.wijsenbeek-lourens@erasmusmc.nl
Maria Molina-Molina
2Dept of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge, Institute for Biomedical Research (IDIBELL), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Chassany
3Patient-Reported Outcomes Research Unit, Université de Paris, Paris, France
4Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP-HP, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Fox
5Foxworthy Healthcare Consulting, Ada, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liam Galvin
6European Idiopathic Pulmonary Fibrosis and Related Disorders Federation, Overijse, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Geissler
7Patient Support Group, Lungenfibrose eV, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine M. Hammitt
8Sjögren's Foundation, Reston, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kreuter
9Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Kreuter
Teng Moua
10Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily C. O'Brien
11Duke Clinical Research Institute, Durham, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley F. Slagle
12Aspen Consulting, LLC, Steamboat Springs, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ashley F. Slagle
Anna Krasnow
13Patient Centred Solutions, IQVIA, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Reaney
14Patient Centred Solutions, IQVIA, Reading, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Baldwin
15Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Male
15Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus B. Rohr
15Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Swigris
16National Jewish Health, Denver, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katerina Antoniou
17Laboratory of Cellular and Molecular Pneumonology, Dept of Respiratory Medicine, School of Medicine, University of Crete, Crete, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Flow of consensus meetings involving stakeholders. PF-ILD: progressive fibrosing interstitial lung disease; PRO: patient-reported outcome.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Important symptoms and impacts reported by participants in the online poll for determining treatment benefit. Other symptoms: chest discomfort 0%, other chest symptoms 0%, runny nose 0%. Other impacts: fear of infection 0%, loss of freedom 0%, oxygen use impacting on activities of daily living (ADLs) 0%, concern for family 0%, anxiety 0%, depression 0%, thoughts of death 0%, implication of disease 0%. SoB: shortness of breath.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    Final conceptual model. Concepts prioritised in the consensus meeting are in red and those prioritised in the online survey are in green. All concepts of high prevalence (at least one literature publication reporting a prevalence of ≥50%) are in bold. Impacts where the relationship to signs and symptoms was indirect/unclear are categorised as distal. PF-ILD: progressive fibrosing interstitial lung disease; DR: disease-related; TR: treatment-related.

  • FIGURE 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4

    Process of developing the conceptual model. Green: prioritisation at online survey; red: prioritisation at consensus meeting. PF-ILD: progressive fibrosing interstitial lung disease. #: muscle loss, stiffness in joints, joint pain and swollen and inflamed joints. ¶: lack of psychological support, lack of satisfaction with healthcare and positive feelings/experiences with healthcare, concerns with diagnosis and need for more disease awareness, being more vigilant towards avoiding antigens. +: symptoms from the online survey were adapted from the preliminary consensus model: three phlegm symptoms (difficulty bringing up phlegm, producing phlegm and bad-tasting phlegm) were grouped together; the shortness of breath (SoB) concept was split into SoB at rest and SoB on exertion; change in appetite added to differentiate from loss of appetite. §: muscular wasting was added as part of the final conceptual model.

  • FIGURE 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5

    a) The most important characteristics of the prioritised concepts; b) the most appropriate recall period; c) the most appropriate response scale reported by participants in the meeting to measure prioritised concepts. The total number of votes was 14 for most concepts, except where participants selected two categories when voting. Data are presented as percentage of total votes, with the actual number of votes shown above each bar. SoB: shortness of breath; ADLs: activities of daily living; VAS: visual analogue scale; NRS: numeric rating scale.

  • FIGURE 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6

    Priority concepts for defining treatment benefit in progressive fibrosing interstitial lung disease (PF-ILD). NRS: numeric rating scale.

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Summary of patient-reported outcome measure (PROM) questionnaires and concepts captured

    Content validityPsychometric propertiesItemsRecall periodResponse scaleSoB on exertionCoughFatiguePhysical functioningADLEmotional wellbeing
    K-BILD [17, 18]Input from patients with ILD (including IPF)Cross-sectional and longitudinal measurement properties established in patients with IPF152 weeks7-point Likert scaleF: 3 itemsINF: 1 itemINF: 1 item
    SGRQ-I [18, 19]Target: IPF
    Rasch analysis using HRQoL data from RCT
    Cross-sectional and/or without longitudinal measurement properties established in patients with IPF34Current/3 months/6 months/12 months3–5-point Likert scaleS: 1 item; INC: 4 itemsS: 2 items; INC: 1 itemINC: 1 itemS: 8 items; INC: 1 item; INF: 2 itemsINC: 5 items;
    INF: 3 items
    L-IPF [20]Input from patients with IPFCross-sectional measurement properties established patients with IPF3524 h (symptoms)
    1 week (impacts)
    0–4 NRS formatS: 7 items; INC: 1 item;
    INF: 3 items
    F: 3 items;
    S: 2 items; INF: 1 item
    S: 3 items; INF: 1 itemS: 6 items;
    INF: 1 item
    S: 5 items;
    INF: 2 items
    L-PF [16]Input from patients with PF-ILDNot available4424 h (symptoms)
    1 week (impacts)
    0–4 NRS formatS: 12 items;
    F: 1 item; INF: 3 items;
    INC: 1 item
    F: 5 items;
    S: 2 items;
    INC: 1 item
    S: 3 items;
    INF: 1 item
    S: 8 items
    INF: 1 item
    S: 7 items;
    INF: 3 items
    CASA-Q [21, 22]Input from patients with chronic bronchitisCross-sectional and longitudinal measurement properties established in patients with COPD and chronic bronchitis201 week5-point Likert scaleF: 2 itemsS: 1 item;
    F: 2 items
    F: 1 itemINF: 2 itemsINF: 4 items
    LCQ [23]Input from patients with chronic coughCross-sectional and longitudinal measurement properties established in patients with chronic cough or COPD192 weeks7-point
    Likert scale
    S: 1 item; F: 1 itemF: 2 itemsINF: 2 items
    E-RS (COPD+IPF) [24, 25]Input from patients with COPDCross-sectional and longitudinal measurement properties established in patients with COPD1124 h5-point
    Likert scale
    S: 5 itemsF: 1 itemS: 1 itemINF: 1 itemINF: 2 items
    Input from patients with IPFCross-sectional and longitudinal measurement properties established in patients with IPF
    FACIT-Dyspnoea [26]Input from patients with dyspnoeaCross-sectional measurement properties established in patients with dyspnoeaItem bank: 33; short form: 101 week4-point Likert scaleS: 34 itemsINF: 12 itemsINF: 18 items
    FACIT-Fatigue [27]Input from patients with anaemic cancerCross-sectional measurement properties established in a mixed cancer patient population401 week5-point Likert scaleS: 7 items
    INF: 1 item
    INF: 3 items
    S: 2 items
    INF: 1 item

    SoB: shortness of breath; ADL: activity of daily living; K-BILD: King’s Brief Interstitial Lung Disease; SGRQ-I: idiopathic pulmonary fibrosis (IPF)-specific version of St George's Respiratory Questionnaire; L-IPF: Living with Idiopathic Pulmonary Fibrosis; L-PF: Living with Pulmonary Fibrosis; CASA-Q: Cough and Sputum Assessment Questionnaire; LCQ: Leicester Cough Questionnaire; E-RS: Evaluating Respiratory Symptoms; FACIT: Functional Assessment of Chronic Illness Therapy; ILD: interstitial lung disease; F: frequency; INF: interference; HRQoL: health-related quality of life; RCT: randomised controlled trial; PF-ILD: progressive fibrosing interstitial lung disease; S: severity; INC: incidence; NRS: numeric rating scale.

    • TABLE 2

      Review of the Living with Pulmonary Fibrosis (L-PF) questionnaire for measuring symptoms and impacts of progressive fibrosing interstitial lung disease (PF-ILD)

      Consensus recommendationRelevant items from the L-PFComments
      Interference on daily life of SoB (on exertion) in past 24 hInterference on daily life of SoB
      Impacts module:
      1) How much did shortness of breath prevent you from doing things you wanted to do?
      2) How much did fear of becoming too short of breath limit your physical exertion?
      17) How has shortness of breath affected your quality of life?
      The L-PF has 17 items measuring the incidence, severity, frequency and interference of SoB upon exertion. Further thought is needed as to whether the three impact items on interference should be used in isolation and how a score would be calculated.
      The recall period for the three items on interference also assesses the past week, rather than 24 h. The other 14 items in the symptoms module assesses SoB over the past 24 h.
      The L-PF response scale (0–4 numeric scale) is consistent with consensus recommendations
      Frequency of cough in past 24 hFrequency of cough
      Symptoms module:
      13) Over the last 24 h, how often did you cough?
      14) Over the last 24 h, how often did you cough when you took a deep breath?
      15) Over the last 24 h, how often did you cough when you were breathing hard or fast?
      16) Over the last 24 h, how often did you cough when you over-exerted yourself?
      17) Over the last 24 h, how often did coughing make you short of breath?
      The L-PF has five items for measuring the frequency of cough over the past 24 h. Three other items assess the severity and incidence of cough.
      Interference on daily life of fatigue in past weekInterference on daily life of fatigue
      Impacts module:
      19) How much has your energy level affected your quality of life?
      The L-PF questionnaire may lack specificity in the impact items for fatigue. There is only one fatigue-related item, which focuses on energy levels.
      If a treatment benefit on fatigue was expected, a fatigue-specific questionnaire may be needed in addition to the L-PF
      Severity of physical functioning limitations in past weekSeverity of physical functioning limitations
      Symptoms module:
      4) How short of breath did walking up a short, gradual incline make you?
      6) How short of breath did walking outside on a level surface make you?
      7) How short of breath did walking from room to room inside your home make you?
      8) How short of breath did getting ready to leave your home (e.g. find keys, put on coat, lock doors) make you?
      10) How short of breath did doing light cleaning around the house make you?
      12) How short of breath did lifting and carrying a light load a short distance make you?
      Impacts module:
      14) How much did you have to pace yourself to make it through the day?
      15) How much time did it take to get yourself ready to leave the house?
      The L-PF has six items in the symptoms module (24 h) and two items in the impacts module (past week) that assess the severity of physical functioning. The items in the symptoms module focus on SoB.
      Severity of ADL limitation in past weekSeverity of ADL limitation
      Symptoms module:
      1) How short of breath did getting dressed make you?
      2) How short of breath did walking up one flight of stairs make you?
      3) Over the last 24 h, how short of breath have you been while sitting down, relaxing, reading or watching TV?
      5) How short of breath did grooming make you?
      6) How short of breath did walking outside on a level surface make you?
      9) How short of breath did bathing or showering make you?
      Impacts module:
      3) How was your stamina when you exerted physically?
      The L-PF has six items in the symptoms module (24 h) and one item in the impacts module (past week) that assess the severity of ADL limitation. The items in the symptoms module focus on SoB.
      Interference on daily life of emotional wellbeing in past weekNANA

      SoB: shortness of breath; ADL: activity of daily living; NA: not applicable.

      Supplementary Materials

      • Figures
      • Tables
      • Supplementary Material

        Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

        Supplementary material 00681-2021.SUPPLEMENT

      PreviousNext
      Back to top
      Vol 8 Issue 2 Table of Contents
      ERJ Open Research: 8 (2)
      • Table of Contents
      • Index by author
      Email

      Thank you for your interest in spreading the word on European Respiratory Society .

      NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

      Enter multiple addresses on separate lines or separate them with commas.
      Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures
      (Your Name) has sent you a message from European Respiratory Society
      (Your Name) thought you would like to see the European Respiratory Society web site.
      CAPTCHA
      This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
      Print
      Citation Tools
      Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures
      Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O'Brien, Ashley F. Slagle, Anna Krasnow, Matthew Reaney, Michael Baldwin, Natalia Male, Klaus B. Rohr, Jeff Swigris, Katerina Antoniou
      ERJ Open Research Apr 2022, 8 (2) 00681-2021; DOI: 10.1183/23120541.00681-2021

      Citation Manager Formats

      • BibTeX
      • Bookends
      • EasyBib
      • EndNote (tagged)
      • EndNote 8 (xml)
      • Medlars
      • Mendeley
      • Papers
      • RefWorks Tagged
      • Ref Manager
      • RIS
      • Zotero
      Share
      Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures
      Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O'Brien, Ashley F. Slagle, Anna Krasnow, Matthew Reaney, Michael Baldwin, Natalia Male, Klaus B. Rohr, Jeff Swigris, Katerina Antoniou
      ERJ Open Research Apr 2022, 8 (2) 00681-2021; DOI: 10.1183/23120541.00681-2021
      del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
      Full Text (PDF)

      Jump To

      • Article
        • Abstract
        • Abstract
        • Introduction
        • Methods
        • Results
        • Discussion
        • Supplementary material
        • Acknowledgements
        • Footnotes
        • References
      • Figures & Data
      • Info & Metrics
      • PDF

      Subjects

      • Interstitial and orphan lung disease
      • Tweet Widget
      • Facebook Like
      • Google Plus One

      More in this TOC Section

      Original Research Articles

      • Functional assay in CF organoids allows drug repurposing
      • Bacterial DNA amplifies neutrophilic inflammation in IL-17-exposed airways
      • PERSPIRE: a cohort study
      Show more Original Research Articles

      Interstitial lung disease

      • Developing a self-management package for pulmonary fibrosis
      • Development and validation of an ILD exposure questionnaire
      • Effect of nintedanib on AEs of fibrosing ILDs
      Show more Interstitial lung disease

      Related Articles

      Navigate

      • Home
      • Current issue
      • Archive

      About ERJ Open Research

      • Editorial board
      • Journal information
      • Press
      • Permissions and reprints
      • Advertising

      The European Respiratory Society

      • Society home
      • myERS
      • Privacy policy
      • Accessibility

      ERS publications

      • European Respiratory Journal
      • ERJ Open Research
      • European Respiratory Review
      • Breathe
      • ERS books online
      • ERS Bookshop

      Help

      • Feedback

      For authors

      • Instructions for authors
      • Publication ethics and malpractice
      • Submit a manuscript

      For readers

      • Alerts
      • Subjects
      • RSS

      Subscriptions

      • Accessing the ERS publications

      Contact us

      European Respiratory Society
      442 Glossop Road
      Sheffield S10 2PX
      United Kingdom
      Tel: +44 114 2672860
      Email: journals@ersnet.org

      ISSN

      Online ISSN: 2312-0541

      Copyright © 2023 by the European Respiratory Society